In this study, the detailed effectiveness of two of the CDK4/6 inhibiting medications used in the first-line treatment of HR+/HER2- stage IV breast cancer patients in Qatar, palbociclib, and ribociclib, as well as their safety profiles were evaluated. This evidence concerns the gene ERBB2 and breast cancer.